Immunogenicity and reactogenicity of the MMR-varicella zoster virus vaccine following a 4-week or a 12-month interval between two doses

Trial Profile

Immunogenicity and reactogenicity of the MMR-varicella zoster virus vaccine following a 4-week or a 12-month interval between two doses

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Mar 2011

At a glance

  • Drugs MMR-varicella zoster virus vaccine (Primary) ; Measles mumps and rubella virus vaccine; Varicella zoster virus vaccine
  • Indications Chickenpox; Measles; Mumps; Rubella
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top